Insider · CIK 0001860131
Paul K. Audhya
officer
Files at KALV (KalVista Pharmaceuticals, Inc.). First filing Nov 19, 2024, latest May 27, 2026.
Paul K. Audhya files SEC Form 4 as officer at KALV (KalVista Pharmaceuticals, Inc.). Since Nov 19, 2024, Paul K. Audhya has reported 0 open-market buys worth $0 and 18 open-market sells worth $779k, the latest filed on May 27, 2026.
A track record needs three past buys with six months of prices behind them; Paul K. Audhya has 0, so none is measured yet.
The newest scored trade: sold $60k of KALV on May 26, 2026, filed May 27, 2026, scored 22 (weak). In the last 12 months: 0 buys worth $0 and 8 sells worth $430k.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 18
$0 bought, $779k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | KalVista Pharmaceuticals, Inc. | $60k 2,239 shares | -1% | - | |
| 23Weak | KalVista Pharmaceuticals, Inc. | $72k 2,685 shares | -2% | - | |
| 20Weak | KalVista Pharmaceuticals, Inc. | $28k 1,032 shares | -1% | - | |
| 22Weak | KalVista Pharmaceuticals, Inc. | $54k 2,686 shares | -2% | - | |
| 24Weak | KalVista Pharmaceuticals, Inc. | $83k 5,354 shares | -4% | - | |
| 15Weak | KalVista Pharmaceuticals, Inc. | $17k 1,163 shares | -1% | - | |
| 23Weak | KalVista Pharmaceuticals, Inc. | $71k 5,296 shares | -4% | - | |
| 21Weak | KalVista Pharmaceuticals, Inc. | $45k 3,075 shares | -2% | - | |
| 20Weak | KalVista Pharmaceuticals, Inc. | $31k 2,336 shares | -2% | - | |
| 21Weak | KalVista Pharmaceuticals, Inc. | $39k 2,942 shares | -2% | - | |
| 21Weak | KalVista Pharmaceuticals, Inc. | $39k 2,939 shares | -2% | - | |
| 15Weak | KalVista Pharmaceuticals, Inc. | $24k 2,146 shares | -2% | - | |
| 20Weak | KalVista Pharmaceuticals, Inc. | $32k 2,689 shares | -2% | - | |
| 21Weak | KalVista Pharmaceuticals, Inc. | $33k 2,776 shares | -3% | - | |
| 15Weak | KalVista Pharmaceuticals, Inc. | $24k 2,394 shares | -2% | - | |
| 20Weak | KalVista Pharmaceuticals, Inc. | $31k 3,125 shares | -3% | - | |
| 15Weak | KalVista Pharmaceuticals, Inc. | $22k 2,187 shares | -2% | - | |
| 23Weak | KalVista Pharmaceuticals, Inc. | $75k 8,077 shares | -8% | - |
Transactions
The newest 50 of 72 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | KALV KalVista Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -150,260 | $0.00 | $0 | 0 | Jun 11, 2026 |
| Jun 11, 2026 | KALV KalVista Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -100,000 | - | - | 0 | Jun 11, 2026 |
| Jun 11, 2026 | KALV KalVista Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,800 | - | - | 0 | Jun 11, 2026 |
| Jun 11, 2026 | KALV KalVista Pharmaceuticals, Inc. | DDisposition to issuer Restricted Stock Unitderivative | -40,000 | - | - | 0 | Jun 11, 2026 |
| Jun 11, 2026 | KALV KalVista Pharmaceuticals, Inc. | DDisposition to issuer Restricted Stock Unitderivative | -68,750 | - | - | 0 | Jun 11, 2026 |
| Jun 11, 2026 | KALV KalVista Pharmaceuticals, Inc. | DDisposition to issuer Restricted Stock Unitderivative | -93,750 | - | - | 0 | Jun 11, 2026 |
| May 22, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +5,000 | - | - | 152,499 | May 27, 2026 |
| May 26, 2026 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,239 | $26.78 | $60k | 150,260 | May 27, 2026 |
| May 22, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 40,000 | May 27, 2026 |
| May 21, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,250 | - | - | 150,184 | May 26, 2026 |
| May 22, 2026 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,685 | $26.78 | $72k | 147,499 | May 26, 2026 |
| May 21, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 68,750 | May 26, 2026 |
| May 17, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +2,419 | - | - | 144,966 | May 19, 2026 |
| May 18, 2026 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,032 | $26.76 | $28k | 143,934 | May 19, 2026 |
| May 17, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -2,419 | $0.00 | $0 | 0 | May 19, 2026 |
| Apr 16, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,250 | - | - | 145,233 | Apr 20, 2026 |
| Apr 17, 2026 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,686 | $20.22 | $54k | 142,547 | Apr 20, 2026 |
| Apr 16, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 93,750 | Apr 20, 2026 |
| Feb 21, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,250 | - | - | 139,337 | Feb 24, 2026 |
| Feb 22, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +5,000 | - | - | 144,337 | Feb 24, 2026 |
| Feb 23, 2026 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -5,354 | $15.57 | $83k | 138,983 | Feb 24, 2026 |
| Feb 21, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 75,000 | Feb 24, 2026 |
| Feb 22, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 45,000 | Feb 24, 2026 |
| Feb 17, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +2,419 | - | - | 134,250 | Feb 19, 2026 |
| Feb 18, 2026 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,163 | $15.00 | $17k | 133,087 | Feb 19, 2026 |
| Feb 17, 2026 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -2,419 | $0.00 | $0 | 2,419 | Feb 19, 2026 |
| Jan 16, 2026 | KALV KalVista Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitderivative | +100,000 | $0.00 | $0 | 100,000 | Jan 21, 2026 |
| Nov 21, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,250 | - | - | 132,127 | Nov 26, 2025 |
| Nov 22, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +5,000 | - | - | 137,127 | Nov 26, 2025 |
| Nov 24, 2025 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -5,296 | $13.45 | $71k | 131,831 | Nov 26, 2025 |
| Nov 21, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 81,250 | Nov 26, 2025 |
| Nov 22, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 50,000 | Nov 26, 2025 |
| Nov 17, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,447 | - | - | 128,952 | Nov 19, 2025 |
| Nov 18, 2025 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,075 | $14.48 | $45k | 125,877 | Nov 19, 2025 |
| Nov 17, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -2,419 | $0.00 | $0 | 4,838 | Nov 19, 2025 |
| Nov 17, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -4,028 | $0.00 | $0 | 0 | Nov 19, 2025 |
| Aug 22, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +5,000 | - | - | 124,841 | Aug 26, 2025 |
| Aug 25, 2025 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,336 | $13.42 | $31k | 122,505 | Aug 26, 2025 |
| Aug 22, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 55,000 | Aug 26, 2025 |
| Aug 21, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,250 | - | - | 122,783 | Aug 25, 2025 |
| Aug 22, 2025 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,942 | $13.22 | $39k | 119,841 | Aug 25, 2025 |
| Aug 21, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 87,500 | Aug 25, 2025 |
| Aug 17, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,446 | - | - | 119,472 | Aug 19, 2025 |
| Aug 18, 2025 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,939 | $13.19 | $39k | 116,533 | Aug 19, 2025 |
| Aug 17, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -2,418 | $0.00 | $0 | 7,257 | Aug 19, 2025 |
| Aug 17, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -4,028 | $0.00 | $0 | 4,028 | Aug 19, 2025 |
| May 22, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +5,000 | - | - | 115,172 | May 27, 2025 |
| May 23, 2025 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,146 | $11.31 | $24k | 113,026 | May 27, 2025 |
| May 22, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 60,000 | May 27, 2025 |
| May 21, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,250 | - | - | 112,861 | May 23, 2025 |
50 of 72 rows shown.
Questions about Paul K. Audhya
Answered from the filings on this page, as of the latest one.
Is Paul K. Audhya buying or selling?
In the last 12 months Paul K. Audhya reported 0 open-market buys worth $0 and 8 open-market sells worth $430k on SEC Form 4; the latest was sold $60k of KALV on May 26, 2026. Grants, option exercises and tax withholding are not counted.
How did Paul K. Audhya's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul K. Audhya has 0.
Where does Paul K. Audhya file Form 4?
Paul K. Audhya has filed Form 4 at KALV (KalVista Pharmaceuticals, Inc.) as CHIEF MEDICAL OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.